首页> 外文期刊>Journal of Analytical Methods in Chemistry >Multicentre evaluation of the Boehringer Mannheim/Hitachi 917 analysis system
【24h】

Multicentre evaluation of the Boehringer Mannheim/Hitachi 917 analysis system

机译:Boehringer Mannheim / Hitachi 917分析系统的多中心评估

获取原文
       

摘要

The new selective access analysis system BM/Hitachi 917 was evaluated in an international multicentre study, mainly according to the ECCLS protocol for the evaluation of analysers in clinical chemistry. Forty-three different analytes, covering 56 different methods enzymes, substrates, electrolytes, specific proteins, drugs and urine applications were tested in seven European clinical chemistry laboratories. Additionally, the practicability of the BM/ Hitachi 917 was tested according to a standardized questionnaire. Within-run CVs (median of 3 days) for enzymes, substrates and electrolytes were <2% except for creatine-kinase MB isoform and lipase at low concentration. For proteins, drugs and urine analytes the within-run CVs were < 4% except for digoxin and albumin in urine. Between-day median CVs were generally < 3% for enzymes, substrates and electrolytes, and < 6% for proteins, drugs and urine analytes, except for lipase, creatine kinase and MB isoform, D-dimer, glycosylated haemoglobin, rheumatoid factors, digoxin, digitoxin, theophylline and albumin in urine in some materials. Linearity was found according to the test specifications or better and there were no relevant effects seen in drift and carry-over testing. The interference results clearly show that also for the BM/Hitachi 917 interference exists sometimes, as could be expected because of the chemistries applied. It is a situation that can be found in equivalent analysers as well. The accuracy is acceptable regarding a 95–105% recovery in standard reference material, with the exception of the creatinine Jaffé method. Most of the 160 method comparisons showed acceptable agreement according to our criteria: enzymes, substrates, urine analytes deviation of slope ± 5%, electrolytes ± 3%, and proteins and drugs ± 10%. The assessment of practicability for 14 groups of attributes resulted in a grading of one–three scores better for the BM/Hitachi 917 than the present laboratory situation. In conclusion, the results of the study showed good analytical performance and confirmed the usefulness of the system as a consolidated workstation in medium-sized to large clinical chemistry laboratories.
机译:新的选择性访问分析系统BM / Hitachi 917在一项国际多中心研究中进行了评估,主要是根据ECCLS协议对临床化学分析仪进行评估。在七个欧洲临床化学实验室测试了43种不同的分析物,涵盖了56种不同的方法,酶,底物,电解质,特定蛋白质,药物和尿液应用。此外,根据标准调查表测试了BM / Hitachi 917的实用性。除低浓度的肌酸激酶MB同工型和脂肪酶外,酶,底物和电解质的运行内CV(中值为3天)<2%。对于蛋白质,药物和尿液分析物,除尿液中的地高辛和白蛋白外,运行内CV小于4%。除脂肪酶,肌酸激酶和MB同工型,D-二聚体,糖基化血红蛋白,类风湿因子,地高辛外,酶,底物和电解质的日间平均CV通常<3%,蛋白质,药物和尿液分析物的<6% ,尿中的洋地黄毒苷,茶碱和白蛋白的某些物质。线性是根据测试规范或更佳的规范得出的,在漂移和残留测试中没有发现相关的影响。干扰结果清楚地表明,对于BM / Hitachi 917,有时也会存在干扰,这是由于所采用的化学方法而可以预期的。在等效分析仪中也可以找到这种情况。关于标准参考物质中95%至105%的回收率(肌酐Jaffé方法除外)的准确性是可以接受的。根据我们的标准,在160种方法的比较中,大多数显示出可接受的一致性:酶,底物,尿液分析物的斜率偏差±5%,电解质±3%,蛋白质和药物±10%。对14组属性的实用性进行评估后,BM / Hitachi 917的得分比当前的实验室情况好1-3分。总之,研究结果显示出良好的分析性能,并确认了该系统作为中型到大型临床化学实验室整合工作站的有用性。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号